New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib

In addition to eradication of Helicobacter pylori, chemotherapy with anticancer agents, and radiation therapy, the treatment with molecular target drugs including rituximab, a CD20 antagonist, is one of the promising new regimens. The mucosa-associated lymphoid tissue (MALT) lymphoma is histological...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Masahiko, Takahashi, Tetsufumi, Matsui, Hidenori, Takahashi, Shinichi, Murayama, Somay Y, Suzuki, Hidekazu, Tsuchimoto, Kanji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260359/
https://www.ncbi.nlm.nih.gov/pubmed/23782142
http://dx.doi.org/10.2174/13816128113199990420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260359/
https://www.ncbi.nlm.nih.gov/pubmed/23782142
http://dx.doi.org/10.2174/13816128113199990420

Ejemplares similares